Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

John Hurvitz Named “Healthcare and Life Sciences Trailblazer”

April 1, 2020

WASHINGTON—The National Law Journal has named Covington's John Hurvitz to its list of “Healthcare and Life Sciences Trailblazers.” This list features 26 honorees who are recognized as “agents of change” whose work has advanced innovation in the health care and life sciences industries.

Mr. Hurvitz co-chairs C&B's Life Sciences Industry Group, heads the firm's Life Sciences Transactions Group and is co-chair of the firm’s Technology Transactions Group. He is a trusted adviser to many leading pharmaceutical, biotechnology, and smaller, emerging companies, which he counsels on a range of corporate, commercial, partnering, and advisory matters. He has extensive experience structuring, negotiating, and documenting sophisticated, multidisciplinary, cross-border collaborations and M&A transactions for clients in the U.S., Europe, and Asia. Mr. Hurvitz also provides strategic advice in enhancing performance with respect to contract execution and management, dispute resolution, and identifying industry best practices in connection with transactional matters.

In its feature, The National Law Journal recognizes Mr. Hurvitz’s work in creating Covington’s multidisciplinary life sciences practice, in helping companies partner to create dozens of transformative therapies and in creating innovative deal structures to address emerging technologies and products, including immuno-oncology, gene and cellular therapies, regenerative medicine and digital and e-health. "Even after all these years, the bar remains small in this practice area because you have to have a deep understanding of IP, corporate, commercial and regulatory issues and bring them together to create complex partnerships that span decades and promote the flexibility and creativity to accomplish one of the most challenging undertakings-drug discovery," said Mr. Hurvitz.

Share this article: